$ATRA
Atara Biotherapeutics, Inc.

2021 Q2 Form 10-Q Financial Statement

#000156459021042636 Filed on August 09, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2
Revenue $3.870M $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $19.40M $16.39M
YoY Change 18.35% -29.6%
% of Gross Profit
Research & Development $68.48M $61.56M
YoY Change 11.23% 17.82%
% of Gross Profit
Depreciation & Amortization $2.320M $2.050M
YoY Change 13.17% 17.82%
% of Gross Profit
Operating Expenses $87.87M $77.95M
YoY Change 12.73% 3.2%
Operating Profit -$84.00M -$77.95M
YoY Change 7.76% 3.2%
Interest Expense $225.0K $500.0K
YoY Change -55.0% -58.68%
% of Operating Profit
Other Income/Expense, Net $225.0K $497.0K
YoY Change -54.73% -58.82%
Pretax Income -$83.78M -$77.46M
YoY Change 8.16% 4.21%
Income Tax $16.00K $1.000K
% Of Pretax Income
Net Earnings -$83.79M -$77.46M
YoY Change 8.18% 4.21%
Net Earnings / Revenue -2165.19%
Basic Earnings Per Share -$0.91
Diluted Earnings Per Share -$0.91 -$1.139M
COMMON SHARES
Basic Shares Outstanding 92.15M
Diluted Shares Outstanding 92.15M

Balance Sheet

Concept 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $373.4M $347.7M
YoY Change 7.39% 82.9%
Cash & Equivalents $123.9M $75.91M
Short-Term Investments $249.5M $273.2M
Other Short-Term Assets $18.95M $11.30M
YoY Change 67.65% 2.73%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $392.3M $359.0M
YoY Change 9.28% 78.48%
LONG-TERM ASSETS
Property, Plant & Equipment $51.03M $53.59M
YoY Change -4.77% -6.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.889M $2.200M
YoY Change -14.14% 589.66%
Total Long-Term Assets $64.47M $69.10M
YoY Change -6.71% -5.35%
TOTAL ASSETS
Total Short-Term Assets $392.3M $359.0M
Total Long-Term Assets $64.47M $69.10M
Total Assets $456.8M $428.1M
YoY Change 6.7% 56.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.30M $5.100M
YoY Change 141.2% -20.56%
Accrued Expenses $28.19M $20.90M
YoY Change 34.9% 50.36%
Deferred Revenue $40.97M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $88.83M $31.70M
YoY Change 180.22% 22.85%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $1.771M $15.30M
YoY Change -88.42% 1238.58%
Total Long-Term Liabilities $1.771M $15.30M
YoY Change -88.42% 1238.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $88.83M $31.70M
Total Long-Term Liabilities $1.771M $15.30M
Total Liabilities $125.3M $47.00M
YoY Change 166.5% 12.27%
SHAREHOLDERS EQUITY
Retained Earnings -$1.287B -$968.9M
YoY Change 32.8% 45.13%
Common Stock $1.618B
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $331.5M $381.1M
YoY Change
Total Liabilities & Shareholders Equity $456.8M $428.1M
YoY Change 6.7% 56.16%

Cashflow Statement

Concept 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$83.79M -$77.46M
YoY Change 8.18% 4.21%
Depreciation, Depletion And Amortization $2.320M $2.050M
YoY Change 13.17% 17.82%
Cash From Operating Activities -$61.58M -$56.64M
YoY Change 8.71% 3.76%
INVESTING ACTIVITIES
Capital Expenditures -$2.058M -$2.080M
YoY Change -1.06% 184.93%
Acquisitions
YoY Change
Other Investing Activities $33.95M -$128.3M
YoY Change -126.46% -351.62%
Cash From Investing Activities $31.89M -$130.4M
YoY Change -124.46% -359.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.449M 191.3M
YoY Change -98.72% 2509.96%
NET CHANGE
Cash From Operating Activities -61.58M -56.64M
Cash From Investing Activities 31.89M -130.4M
Cash From Financing Activities 2.449M 191.3M
Net Change In Cash -27.24M 4.300M
YoY Change -733.44% 43.81%
FREE CASH FLOW
Cash From Operating Activities -$61.58M -$56.64M
Capital Expenditures -$2.058M -$2.080M
Free Cash Flow -$59.52M -$54.56M
YoY Change 9.09% 1.3%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q2 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
2599000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13807000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2012-08-01
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-77455000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.91
CY2021Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
1231000
CY2021Q1 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
1749000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12268000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-78335000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-135000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
399037000
CY2021Q2 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
13000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-83793000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-99000
CY2020Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
1395000
CY2020Q1 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
1330000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1250000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-150964000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-83793000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-77456000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
606000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-83892000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-162112000
CY2021Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
22470000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12182000
CY2021Q2 atra License And Collaboration Revenue
LicenseAndCollaborationRevenue
3870000
CY2021Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
40968000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
84754000
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
8000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
456791000
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1771000
CY2021Q2 us-gaap Liabilities
Liabilities
125253000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
33430000
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
84754000
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1618177000
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
62000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1286709000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
331538000
atra License And Collaboration Revenue
LicenseAndCollaborationRevenue
0
us-gaap Operating Expenses
OperatingExpenses
169669000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
225000
us-gaap Operating Expenses
OperatingExpenses
152649000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-77952000
us-gaap Operating Income Loss
OperatingIncomeLoss
-162247000
us-gaap Operating Income Loss
OperatingIncomeLoss
-152649000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
497000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
135000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1685000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-83777000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
16000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
16000
us-gaap Net Income Loss
NetIncomeLoss
-150965000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-234000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
590000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-76850000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-162362000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-150375000
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.14
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.77
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.34
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
92152000
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
67975000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
91806000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
64592000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2188000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12644000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-73509000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-16000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
252822000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2419000
atra Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-837000
atra Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-535000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-250000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
541000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-127275000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-123680000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
158869000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
228224000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
208515000
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
140235000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4258000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3409000
CY2020Q4 us-gaap Interest Receivable
InterestReceivable
700000
CY2021Q2 us-gaap Interest Receivable
InterestReceivable
700000
atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
CY2020 atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
CY2021Q2 us-gaap Restricted Cash
RestrictedCash
1400000
atra Non Cash Investing And Financing Activities Accrued Costs Related To Underwritten Public Offering
NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering
0
atra Non Cash Investing And Financing Activities Accrued Costs Related To Underwritten Public Offering
NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering
322000
atra Finance Lease Assets Obtained In Exchange For Lease Obligations
FinanceLeaseAssetsObtainedInExchangeForLeaseObligations
0
atra Finance Lease Assets Obtained In Exchange For Lease Obligations
FinanceLeaseAssetsObtainedInExchangeForLeaseObligations
281000
us-gaap Interest Paid Net
InterestPaidNet
37000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
7000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
1400000
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
75094000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
70193000
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
24065000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
19676000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
51029000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50517000
CY2021Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2300000
CY2020Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2100000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4500000
CY2021Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
69541000
CY2021Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
69526000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
64221000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
64322000
CY2021Q2 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
367935000
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
367998000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
499049000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
499345000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions, and judgments that affect the amounts reported in the financial statements and accompanying notes. Significant estimates relied upon in preparing these financial statements include estimates related to revenue recognition, clinical study and other accruals, stock-based compensation expense and income taxes. Actual results could differ materially from those estimates. </p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14460256
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11917445
CY2021Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
298394000
CY2021Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
298472000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
434828000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
435023000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4000000.0
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
123856000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
200404000
CY2021Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
194000
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
194000
CY2021Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1200000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1200000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
125250000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
201798000
CY2021Q2 atra Due To Licensors Current And Noncurrent
DueToLicensorsCurrentAndNoncurrent
0
CY2020Q4 atra Due To Licensors Current And Noncurrent
DueToLicensorsCurrentAndNoncurrent
0
CY2021Q2 atra Accrued Termination Charges
AccruedTerminationCharges
0
CY2020Q4 atra Accrued Termination Charges
AccruedTerminationCharges
0
CY2021Q2 atra Liabilities Related To Indemnification Agreements
LiabilitiesRelatedToIndemnificationAgreements
0
CY2020Q4 atra Liabilities Related To Indemnification Agreements
LiabilitiesRelatedToIndemnificationAgreements
0
CY2021Q2 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
520000000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
the exercise price of an option granted to a 10% shareholder cannot be less than 110% of the estimated fair value of the shares on the date of grant. Options granted generally vest over four years and expire in seven to ten years.
atra Shareholder Ownership Percent
ShareholderOwnershipPercent
0.10
CY2021Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
20293665
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13807000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13948000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26075000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26592000

Files In Submission

Name View Source Status
0001564590-21-042636-index-headers.html Edgar Link pending
0001564590-21-042636-index.html Edgar Link pending
0001564590-21-042636.txt Edgar Link pending
0001564590-21-042636-xbrl.zip Edgar Link pending
atra-10q_20210630.htm Edgar Link pending
atra-10q_20210630_htm.xml Edgar Link completed
atra-20210630.xsd Edgar Link pending
atra-20210630_cal.xml Edgar Link unprocessable
atra-20210630_def.xml Edgar Link unprocessable
atra-20210630_lab.xml Edgar Link unprocessable
atra-20210630_pre.xml Edgar Link unprocessable
atra-ex101_176.htm Edgar Link pending
atra-ex311_11.htm Edgar Link pending
atra-ex312_7.htm Edgar Link pending
atra-ex321_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending